| Market Capitalization (Millions $) |
162 |
| Shares
Outstanding (Millions) |
112 |
| Employees |
49 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-128 |
| Cash Flow (TTM) (Millions $) |
45 |
| Capital Exp. (TTM) (Millions $) |
4 |
Tscan Therapeutics Inc
Tscan Therapeutics Inc. is a biotechnology company that specializes in the field of immunotherapy. The company focuses on developing and commercializing T cell receptor (TCR) engineered T cell therapies for the treatment of various types of cancer. TCRs are proteins found on the surface of T cells that recognize and bind to specific targets on cancer cells.
Tscan Therapeutics uses its proprietary TCR-engineering technology to modify T cells, enhancing their ability to recognize and eliminate cancer cells. The company's approach aims to leverage the natural power of the immune system to selectively target and destroy cancer cells while sparing healthy cells.
The company's research and development efforts are centered around identifying novel TCRs, engineering T cells with these receptors, and conducting preclinical and clinical studies to assess the safety and efficacy of their therapies. Tscan Therapeutics has also entered into collaborations and partnerships with other companies and academic institutions to strengthen its research capabilities and accelerate the development of its pipeline.
Overall, Tscan Therapeutics Inc. aims to revolutionize cancer treatment by harnessing the potential of T cell immunotherapies to offer more effective and targeted therapies for patients.
Company Address: 830 Winter Street Waltham 2451 MA
Company Phone Number: 399-9500 Stock Exchange / Ticker: NASDAQ TCRX
|
3.81%